Koninklijke Philips stock
PHIA.ASAMSKoninklijke Philips N.V., HealthcareISIN NL0000009538
56Score 56 out of 100, Neutral
Price and trend
64 / 100
Price history
+7.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 83).
The price is 1.1% below its 52-week high. Largest decline in 20 years: 76% (April 2021 to November 2022).
Chart figures for advanced users
- SMA 50$25.69
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)83
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$23.52
- The lowest closing price of the last twelve months.
- Resistance$30.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Koninklijke Philips N.V. belongs to the Medical (Devices) industry (Netherlands) and, with a market value of $29.65B, is number 10 of 90 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $20.06B (up 1.1%) and adjusted earnings per share of $1.84 (up 5.7%).
- MEQIRI Score 56 out of 100 (Neutral): rank 328 of 714 in Healthcare, median 53.
Show more
- The P/E is 28.3 (Medical (Devices) median 29, own median of recent years 24.7).
- Our model puts fair value at $32.03, with the price 6% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 221% of earnings over the last 12 months.Fundamentals 70
- High dividend yieldDividend yield 3.13%, Medical (Devices) median 1.68%.Capital allocation 55
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are momentum and fundamentals, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- price near its 52-week high
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $24.64 and expensive above $45.76 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $32.91 (cash-flow model) and $31.15 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 7.5%. At 8.5% the fair value would be $29.23, at 6.5% it would be $36.17.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 0.1% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 45%, operating 9%, net 5%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 1 Feb 2027in 81 days
- Last reported
- 3 Nov 2026EPS reported $0.45 (expected $0.39)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.84+1.8%
- Revenue
- $20.06B+0.5%
- Earnings per share
- $1.87+0.8%
- Revenue
- $21.02B+0.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.1%Comparable sales growth outlook of 3% to 4.5% and the underlying margin outlook reiterated; reported margin and free cash flow (EUR 1.5 billion to EUR 1.7 billion) raised due to a tariff refund.
“Against this backdrop, we reiterate our full year comparable sales growth outlook range of 3% to 4.5% and our underlying adjusted EBITA margin outlook also remains unchanged. Excluding the tariff refund benefit, we continue to expect a full year adjusted EBITA margin of 12.5% to 13%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Koninklijke Philips
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Siemens HealthineersSHL.DE $54.2B65
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
- Terumo4543.T $23.31B76
- Zimmer Biomet HoldingsZBH $20.34B68
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
ETFs that hold Koninklijke Philips
Held by 116 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.99% | 0.49% | €318.39M |
| Deka EURO iSTOXX ex Fin Dividend+ UCITS ETFELFC | 1.92% | 0.31% | €385.1M |
| WisdomTree Europe Equity UCITS ETF USD HedgedWTDH | 1.31% | 0.58% | €117.51M |
Show 5 more
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 1.22% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 1.21% | 0.18% | €954.9M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 1.21% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 1.17% | 0.46% | €729.65M |
| iShares Inclusion and Diversity UCITS ETFOPEN | 1.17% | 0.25% | €76.52M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.